Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00204542
Status:
COMPLETED
Last Update Posted:
2011-08-19
First Post:
2005-09-13
Brief Title:
Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Comparison of the Efficacy and Tolerability of Solaraze for 3 vs 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Topical treatment of mild to moderate actinic keratosis located on the face and head with Solaraze is known to be a safe and efficient treatment option However it is unclear if an expansion of the treatment period to 6 months will increase the rate of complete responses
Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze applied twice daily to the face and head over 3 or 6 months of treatment
Therefore the investigators will evaluate the efficacy and safety of the treatment of actinic keratosis with Solaraze applied twice daily to the face and head over 3 or 6 months of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudra-CT-Nr 2004-002761-21 | None | None | None |